Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Invitae Corp. (NYSE: NVTA).

Full DD Report for NVTA

You must become a subscriber to view this report.


Recent News from (NYSE: NVTA)

New Study Published in Journal of Clinical Oncology Supports Universal Genetic Testing for all Breast Cancer Patients
SAN FRANCISCO , Dec. 10, 2018 /PRNewswire/ -- Current guidelines for genetic testing of breast cancer patients miss as many patients with pathogenic variants (or genetic mutations) as they find, according to a new study published in the Journal of Clinical Oncology by researchers fro...
Source: PR Newswire
Date: December, 10 2018 07:30
Detailed Research: Economic Perspectives on United Technologies, Walmart, Invitae, Emergent Biosolutions, U.S. Physical Therapy, and Amdocs - What Drives Growth in Today's Competitive Landscape
NEW YORK, Dec. 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of United Technologies Corporation (NYSE:UTX), Walmart Inc. (NYSE:WMT), I...
Source: GlobeNewswire
Date: December, 04 2018 08:15
FDA nod for Loxo's larotrectinib a positive for cancer genetic testing providers
Providers of molecular diagnostic testing services may see some action today on the heels of the FDA's approval for Loxo Oncology's VITRAKVI (larotrectinib) since it is the first cancer drug that will require prospective patients to have their DNA sequenced. More news on: Biocept, Inc., My...
Source: SeekingAlpha
Date: November, 27 2018 07:15
Invitae Corporation (NVTA) CEO Sean George on Q3 2018 Results - Earnings Call Transcript
Invitae Corporation (NVTA) Q3 2018 Results Conference Call November 07, 2018 04:30 PM ET Executives Laura D'Angelo - Investor Relations Sean George - Chief Executive Officer Shelly Guyer - Chief Financial Officer Bob Nussbaum - Chief Medical Officer Lee Bendekgey - Chief Oper...
Source: SeekingAlpha
Date: November, 07 2018 20:25
Invitae beats by $0.02, beats on revenue
Invitae (NYSE: NVTA ): Q3 GAAP EPS of -$0.45 beats by $0.02 . Revenue of $37.4M (+106.6% Y/Y) beats by $2.6M . Shares +5.8% . Press Release More news on: Invitae, Earnings news and commentary, Stocks on the move, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 07 2018 16:30
Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume in Third Quarter 2018
SAN FRANCISCO , Nov. 7, 2018 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced financial and operating results for the third quarter ended September 30, 2018 . Based on progress in the quarter, Invitae is raising its...
Source: PR Newswire
Date: November, 07 2018 16:05
Notable earnings after Wednesday's close
AAOI , ADT , ALB , ALRM , AMBC , ANGI , ANSS , ARNA , ATO , AVID , AVLR , AYX , BREW , CABO , CARG , CASA , CISN , CSGS , CSOD , CTRP , CVNA , CYBR , DVA , ECPG , EDIT , ENS , ENV , ET , EVC , EVRG , FARM , FG , FLO , FLS , FOSL , GDOT , GKOS , HK , HO...
Source: SeekingAlpha
Date: November, 06 2018 17:35
Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria
SAN FRANCISCO , Oct. 29, 2018 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, announced today it has expanded its partnership with Alnylam Pharmaceuticals , the leading RNAi therapeutics company, to provide genetic testing at no cos...
Source: PR Newswire
Date: October, 29 2018 07:30
Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers - New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Invitae Corporation (NYSE:NVTA), Aerie Pharmaceuticals, Inc. (NASDAQ:A...
Source: GlobeNewswire
Date: October, 25 2018 08:30
Invitae to announce third quarter 2018 financial results on November 7, 2018
SAN FRANCISCO , Oct. 24, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018 and will host a conference call and webinar that d...
Source: PR Newswire
Date: October, 24 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1413.6713.6213.7313.021,055,473
2017-04-2410.5010.3910.5410.33118,749
2017-04-2110.5210.3810.5810.33165,879
2017-04-2010.3810.5310.5510.31138,718
2017-04-1910.4110.3710.5810.37129,492

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1412,69641,03830.9372Cover
2018-12-135,94219,41630.6036Cover
2018-12-1211,57042,95026.9383Cover
2018-12-1112,20740,72629.9735Cover
2018-12-1011,20634,61432.3742Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NVTA.


About Invitae Corp. (NYSE: NVTA)

Logo for Invitae Corp. (NYSE: NVTA)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $488,577,166 - 05/25/2018
  • Issue and Outstanding: 67,204,562 - 04/27/2018

 


Recent Filings from (NYSE: NVTA)

Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: September, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 11 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: September, 07 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: August, 24 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: August, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 12 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: May, 22 2018

 

 


Daily Technical Chart for (NYSE: NVTA)

Daily Technical Chart for (NYSE: NVTA)


Stay tuned for daily updates and more on (NYSE: NVTA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: NVTA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NVTA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NVTA and does not buy, sell, or trade any shares of NVTA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/